Metabolomics and metabolic diseases: where do we stand?

CB Newgard - Cell metabolism, 2017 - cell.com
Metabolomics, or the comprehensive profiling of small molecule metabolites in cells, tissues,
or whole organisms, has undergone a rapid technological evolution in the past two decades …

Cardiovascular metabolomics

RW McGarrah, SB Crown, GF Zhang, SH Shah… - Circulation …, 2018 - Am Heart Assoc
Disturbances in cardiac metabolism underlie most cardiovascular diseases. Metabolomics,
one of the newer omics technologies, has emerged as a powerful tool for defining changes …

Catabolic defect of branched-chain amino acids promotes heart failure

H Sun, KC Olson, C Gao, DA Prosdocimo, M Zhou… - Circulation, 2016 - Am Heart Assoc
Background—Although metabolic reprogramming is critical in the pathogenesis of heart
failure, studies to date have focused principally on fatty acid and glucose metabolism …

Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study

C Stegemann, R Pechlaner, P Willeit, SR Langley… - Circulation, 2014 - Am Heart Assoc
Background—The bulk of cardiovascular disease risk is not explained by traditional risk
factors. Recent advances in mass spectrometry allow the identification and quantification of …

Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression

R Wang, B Li, SM Lam, G Shui - Journal of genetics and genomics, 2020 - Elsevier
Mass spectrometry (MS)-based omics technologies are now widely used to profile small
molecules in multiple matrices to confer comprehensive snapshots of cellular metabolic …

Acylcarnitines: reflecting or inflicting insulin resistance?

MG Schooneman, FM Vaz, SM Houten, MR Soeters - Diabetes, 2013 - Am Diabetes Assoc
The incidence of obesity and insulin resistance is growing, and the increase in type 2
diabetes mel-litus (DM2) constitutes one of the biggest challenges for our healthcare …

Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - Am Heart Assoc
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects

SE Reuter, AM Evans - Clinical pharmacokinetics, 2012 - Springer
L-Carnitine (levocarnitine) is a naturally occurring compound found in all mammalian
species. The most important biological function of L-carnitine is in the transport of fatty acids …

Adjusting for heritable covariates can bias effect estimates in genome-wide association studies

H Aschard, BJ Vilhjálmsson, AD Joshi, AL Price… - The American Journal of …, 2015 - cell.com
In recent years, a number of large-scale genome-wide association studies have been
published for human traits adjusted for other correlated traits with a genetic basis. In most …

The role of mitochondria in the pathogenesis of type 2 diabetes

ME Patti, S Corvera - Endocrine reviews, 2010 - academic.oup.com
The pathophysiology of type 2 diabetes mellitus (DM) is varied and complex. However, the
association of DM with obesity and inactivity indicates an important, and potentially …